Investigational drug · Phase 2
NKX019
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lupus Nephritis, Primary Membranous Nephropathy, Systemic Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "NKX019"
First trial start
2024
Jun 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NKX019", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lupus Nephritis
- Primary Membranous Nephropathy
- Systemic Sclerosis
- Idiopathic Inflammatory Myopathies
- Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Lupus (SLE) · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "NKX019" as an intervention, largest first.
Nkarta, Inc.Industry
NCT06733935 · 240 participants (planned) · Start Nov 4, 2024 · Primary completion Oct 2028
Drug: NKX019; Fludarabine and 1 more · For: Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and 1 more
Sites: Los Angeles, California; Plantation, Florida; Tampa, Florida · 12 sites in all
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersActive, not recruiting
Nkarta, Inc.Industry
NCT05020678 · 150 participants (planned) · Start Aug 20, 2021 · Primary completion Mar 31, 2025
Drug: NKX019 · For: Lymphoma, Non-Hodgkin; B-cell Acute Lymphoblastic Leukemia; Large B-cell Lymphoma and 7 more
Sites: Denver, Colorado; Cleveland, Ohio; Camperdown, Australia · 6 sites in all
Nkarta, Inc.Industry
NCT06557265 · 120 participants (planned) · Start Jun 13, 2024 · Primary completion Apr 2027
Drug: NKX019; Fludarabine, Cyclophosphamide · For: Lupus Nephritis; Primary Membranous Nephropathy
Sites: Little Rock, Arkansas; Tustin, California; Gainesville, Florida · 19 sites in all
- A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus ErythematosusEnrolling by invitation
Hospital for Special Surgery, New YorkAcademic, hospital or other
NCT06518668 · 6 participants (planned) · Start Jul 1, 2024 · Primary completion Dec 2026
Drug: NKX019; Cyclophosphamide LD · For: Systemic Lupus Erythematosus
Sites: New York, New York · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lupus Nephritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- IPG11406Phase 23 trials
Nanjing Immunophage Biotech Co., Ltd · Lupus Nephritis, Moderately to Severely Active Ulcerative Colitis (UC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.